Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02762123 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02762123 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 28 participants.
The verdict
NCT02762123, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The study is being conducted to assess the effect of BMS-986142 on the single-dose PK parameters of montelukast, flurbiprofen, omeprazole, midazolam, and digoxin, probe drugs for (cytochome P450) CYP2C8, CYP2C9, CYP2C19, CYP3A4, and P-glycoprotein (P-gp), respectively.
Interventions
- DRUG BMS-986142 200mg
- DRUG BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)
- DRUG BMS-986142 350mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-05 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02762123
The ClinicalTrials.gov registry entry for NCT02762123 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BMS-986142 200mg is the first listed.
NCT02762123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02762123 about?
NCT02762123 is a clinical study titled "A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates". The study is being conducted to assess the effect of BMS-986142 on the single-dose PK parameters of montelukast, flurbiprofen, omeprazole, midazolam, and digoxin, probe drugs for (cytochome P450) CYP2C8, CYP2C9, CYP2C19, CYP3A4, and P-glycoprotein (P-gp), respectively.
What is the current status of trial NCT02762123?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-05. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02762123?
The interventions under investigation include: BMS-986142 200mg (DRUG), BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin) (DRUG), BMS-986142 350mg (DRUG).
Who is sponsoring clinical trial NCT02762123?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.